DOJ reaches $8B settlement with OxyContin maker Purdue Pharma for opioid crisis role

Purdue Pharma logo

The U.S. Department of Justice (DOJ) on Wednesday announced an $8 billion settlement with OxyContin maker Purdue Pharma, widely blamed for fueling the opioid epidemic in the country.

Purdue will make a direct payment to the government of $225 million, which is part of a bigger $2 billion criminal forfeiture. The company also faces a $3.54 billion criminal fine and will also agree to $2.8 billion in damages to resolve its civil liability.

While the settlement resolves criminal and civil probes into how Purdue Pharma marketed its painkillers, the company is tied up in bankruptcy proceedings and lacks the assets to pay the full amount.

Signup for the USA Herald exclusive Newsletter

Purdue Pharma is repurposing its assets for public benefit

“We reached today’s agreement in order to facilitate a global resolution that directs substantial funding to communities in need, rather than to years of legal proceedings,” DOJ said in its statement.

“The abuse and diversion of prescription opioids have contributed to a national tragedy of addiction and deaths, in addition to those caused by illicit street opioids,” said Deputy Attorney General Jeffrey A. Rosen. “With criminal guilty pleas, a federal settlement of more than $8 billion, and the dissolution of a company and repurposing its assets entirely for the public’s benefit, the resolution in today’s announcement re-affirms that the Department of Justice will not relent in its multi-pronged efforts to combat the opioids crisis.”

Purdue Pharma is pleading guilty on three counts: two anti-kickback-related raps and one charge of defrauding the United States.

Rosen said the announcement re-affirms that the DOJ “will not relent in its multi-pronged efforts to combat the opioids crisis.”

According to the plea agreement and subject to bankruptcy court approval, Rosen said the company is poised to be dissolved and “won’t exist in its current form.”